RSV vaccine in older people reduced risk of hospitalization
On Sep. 4, 2024, researcher led by the Centers for Disease Control and Prevention (CDC) and Vanderbilt University…
On Sep. 4, 2024, researcher led by the Centers for Disease Control and Prevention (CDC) and Vanderbilt University…
On Jul. 8, 2024, a study reported that babies exposed to maternal RSV (respiratory syncytial virus) vaccination in…
On Jun. 10, 2024, Roche announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use…
On May 31, 2024, Moderna announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345),…
On Jan. 4, 2024, AstraZeneca Sanofiï¾’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, was approved in China for the…
On Nov. 23, 2023, the World Health Organization (WHO) announced that it was monitoring data from Chinese surveillance…
On Nov. 16, 2023, the CDC announced the release of more than 77,000 additional doses of Beyfortusï¾™ (nirsevimab-alip…
On Nov. 6, 2023, the U.S. Centers for Disease Control and Prevention (CDC) announced that it was conducting…
On Aug. 21, 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved ABRYSVO (Respiratory…
On Aug. 1, 2023, BD announced that the U.S. Food and Drug Administration (FDA) 510(k) had provided clearance…
On Jul. 17, 2023, the FDA approved AstraZeneca’s Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV)…
On Jun. 29, 2023, the Centers for Disease Control and Prevention (CDC) endorsed the CDC Advisory Committee on…
On May 31, 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved ABRYSVO (Respiratory…
On May 3, 2023, the U.S. FDA approved GlaxoSmithKline’s Arexvy as the first respiratory syncytial virus (RSV) vaccine…
On Apr. 27, 2023, Pfizer announced that experimental respiratory syncytial virus (RSV) vaccine was 82% effective in preventing…
On Apr. 5, 2023, Pfizer announced that experimental respiratory syncytial virus (RSV) vaccine was 82% effective in preventing…
On Feb. 8, 2023, BD announced that it had received Emergency Use Authorization from the U.S. Food and…
On Jan. 17, 2023, Moderna announced positive topline data from its ConquerRSV Phase 3 pivotal efficacy trial of…
On Dec. 21, 2022, the U.S. Department of Health and Human Services (HHS), through the Administration for Strategic…
On Dec. 7, 2022, Pfizer announced that the U.S. Food and Drug Administration (FDA) had accepted for priority…
On Nov. 2, 2022, Hologic announced that it had been awarded a $19 million contract from the Biomedical…
On Nov. 1, 2022, Pfizer announced positive top-line data from the Phase 3 clinical trial (NCT04424316) MATISSE (MATernal…
On Jun. 30, 2022, BD (Becton, Dickinson) announced that the BD MAX Respiratory Viral Panel (RVP), a new…
On May 18, 2022, LabCorp announced the receipt of Emergency Use Authorization (EUA) from the U.S. Food and…
On Jan, 25, 2022, Cepheid announced that Health Canada has issued Cepheid a medical device license for Xpert…
On Oct. 14, 2021, Cepheid announced it had received the CE mark for Xpert Xpress CoV-2/Flu/RSV plus, a…
On Oct. 7, 2021, PerkinElmer announced that the U.S. Food and Drug Administration (FDA) had issued Emergency Use…
On Sept. 29, 2021, Cepheid announced it had received Emergency Use Authorization from the U.S. Food & Drug…
On Aug. 3, 2021, Moderna announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track…
On Mar. 9, 2021, Luminex announced that it had submitted an Emergency Use Authorization application to the U.S….